IBI362 Pharmacokinetics Explored in Patients with Kidney Impairment

Understanding the pharmacokinetics (PK) of a new drug like IBI362 – how the body absorbs, distributes, metabolizes, and excretes it – is fundamental for safe and effective dosing. Patients with renal impairment (reduced kidney function) often process drugs differently, which can lead to altered drug levels, impacting efficacy or increasing the risk of side effects. This study specifically aimed to determine how varying degrees of kidney function affect the PK profile of IBI362.

The primary objective of this study was to characterize the PK profile of IBI362 across different levels of renal impairment. While specific numerical results regarding Cmax and AUC values for each group are not detailed in this public record, the study successfully completed enrollment with 20 actual participants. The study aimed to provide critical data on how IBI362's exposure and clearance are affected by impaired kidney function, which is essential for establishing appropriate dosing guidelines. Researchers collected extensive data over 56 days to assess the full elimination profile of the drug. The completion of this Phase 1 study indicates that the necessary samples for PK analysis have been gathered, and the data is now being processed to determine if renal impairment significantly alters IBI362's absorption, distribution, metabolism, or excretion.